GREENVILLE, S.C. and TAMPA, Fla.—Eye Health America (EHA), an ophthalmic provider backed by private equity and offering strategic and operational support to practice groups and ambulatory surgery centers (ASCs) in the Southeast, has announced a preferred partnership supply agreement with Verséa Ophthalmics, Inc. Based in Tampa, Fla., Verséa Ophthalmics specializes in comprehensive ocular point-of-care diagnostic and therapeutic interventions. Under this new agreement, Verséa will supply its human amniotic membrane product and cutting-edge tear-based point-of-care (T-POC) Quantitative Testing Platform, according to the announcement.

The agreement calls for Verséa Ophthalmics to provide its Biovance and Biovance 3L Ocular as the preferred dehydrated human amniotic membrane tissue products used within EHA practices and ASCs to support the treatment of ocular surface disease and ocular surgical applications. In addition, EHA will pilot Verséa’s POC testing platform in select offices prior to a staged expansion on a group-wide basis.

Biovance and Biovance 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix, according to Verséa Ophthalmics. The T-POC Quantitative Testing platform is used in the diagnosis and management of patients suffering from ocular surface disease (OSD).

“We are delighted to establish this new partnership with Verséa Ophthalmics which will allow our eyecare professionals to utilize the T-POC Quantitative Testing Platform and Biovance and Biovance 3L Ocular products to deliver more targeted diagnostic and therapeutic solutions to improve patient care for their ocular surface disease patients and for patients undergoing ocular surgery,” said John Swencki, co-CEO of EHA. “I am confident that Verséa Ophthalmics will be an outstanding partner to EHA practices and surgery centers to provide the best options for the patients our clinics and ASCs serve.”

“Our preferred partnership supply agreement with EHA allows us to deliver a novel point-of-care testing platform to inform treatment decisions and a unique decellularized, ringless, advanced placental-sourced tissue product line to more patients suffering from ocular surface diseases or undergoing ocular surgery,” said Rob Sambursky, MD, president, Verséa Ophthalmics, Inc. “As a corneal specialist myself, I know how important it is to specifically identify and treat underlying disease and have witnessed firsthand how innovative tissue-based ocular therapeutic interventions can improve patient outcomes for ocular surface diseases and ocular surgery.” 

Terms of the agreement were not disclosed.